lentivirus

(redirected from Lentiviral)
Also found in: Medical.

len·ti·vi·rus

 (lĕn′tĭ-vī′rəs)
n. pl. len·ti·vi·rus·es
Any of a group of retroviruses of the genus Lentivirus that cause diseases with a long latent period and a slow, progressive course. HIV is a lentivirus.

[New Latin Lentivīrus, genus name : Latin lentus, slow + virus.]

lentivirus

(ˈlɛntɪˌvaɪrəs)
n
(Microbiology) any of a group of slowly acting viruses that includes the human immunodeficiency virus (HIV), which causes AIDS
[C20: from Latin lentus slow + virus]

len•ti•vi•rus

(ˈlɛn təˌvaɪ rəs)

n., pl. -rus•es.
any slow virus of the genus Lentivirus, of the retrovirus family, causing brain disease in sheep and other animals.
[1980–85; lenti (cular) + virus]
Mentioned in ?
References in periodicals archive ?
Pacheco received multiple co-authored patents for novel gene therapy technologies at the Lentiviral Research Group at Cell Genesys, Inc in Foster City, CA.
Objective: This application proposes experiments to address one of the greatest challenges in HIV vaccine research: how can broadly neutralising antibodies be induced by vaccination in humans to target pathogens such as HIV, which are resistant to traditional vaccine approaches The researcher and host labs will develop a mammalian display system using lentiviral vectors to express HIV proteins on the surface of mammalian cells and allow the in vitro evolution of different candidate vaccine immunogens in the outgoing host lab of Prof.
Lentiviral vector-based vaccine achieved significant control of viral load in monkeys
Omnia will provide lentiviral vector technical services as well as manufacture of research grade through cGMP grade materials.
The bio pharmaceutical company Oxford BioMedica has been selected by healthcare specialist Novartis to make batches of a lentiviral vector for immunotherapy programmes in a deal worth between Au2.
VIRxSYS Corporation announced today that the company has received a grant from the Maryland Stem Cell Research Commission to develop safer methods for induced pluripotent stem cell (iPS) using the company's proprietary spliceosome-mediated RNA trans-splicing (SMaRT[TM]) and lentiviral gene delivery platform technologies.
M2 PHARMA-February 5, 2018-Avrobio Closes USD 60m Financing to Advance Gene Therapy Pipeline and Expand Lentiviral Platform
The combined company will focus on developing and advancing its pipeline of gene therapies based on lentiviral virus and adeno-associated virus gene therapy platforms, with a focus on treating devastating rare diseases.
In this study, Lentiviral vector containing LXR[alpha] shRNAs were constructed and transferred in bovine muscle satellite cells.
The research team at ImmunoCellular successfully packaged a T cell receptor (TCR) DNA sequence into a lentiviral vector, which was then used to transfect human hematopoietic stem cells.
Day 1: Development of a Lentiviral Vector Platform for the Treatment of Chronic Ocular Disease